Pfizer (PFE)
(Delayed Data from NYSE)
$30.77 USD
+0.59 (1.95%)
Updated Jul 26, 2024 04:01 PM ET
After-Market: $30.70 -0.07 (-0.23%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Pfizer Inc. [PFE]
Reports for Purchase
Showing records 521 - 540 ( 568 total )
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Initial Overview of Planned Animal Health Spinoff
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Cost Reduction Leads to Higher Second Quarter EPS
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
1Q Results Impacted by the Lipitor Patent Expiration. Nestle to Purchase Nutrition Unit
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Specialty Pharmaceuticals Short Interest Analysis
Provider: AURIGA USA
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Griffin Securities Updates Coverage on Lpath, Inc. (LPTN)
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Overall near term outlook remains quite encouraging despite slight downward revision to anagement?s CY12 guidance & Lipitor?s patent expiry.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
4Q Revenue and EPS Ahead of Estimates Despite Lower Lipitor Sales and Less Currency Benefit.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Technical Takeaways: Bullish Sector Rotation Continues; Pharmaceutical ETF may be Topping.
Provider: AURIGA USA
Analyst: ALBANESE G
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Technical Takeaways: Bullish Sector Rotation Continues; Pharmaceutical ETF may be Topping.
Provider: AURIGA USA
Analyst: ALBANESE G
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Dividend Increase, Share Repurchase, Management Changes
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Overall near term outlook still remains quite encouraging despite Lipitor?s patent expiry.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
3Q Revenue and EPS Ahead of Expectations. Lipitor Patent Expiration Approaching
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S